Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20113215 | 1.00 | KMT2A (0.37) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL464765 | 1.00 | KMT2A (0.37) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL4886758 | 0.81 | POLB (0.43) | KMT2AMEN1ATMALDH1A1LMNA | |
| SCHEMBL4886754 | 0.81 | POLB (0.43) | KMT2AMEN1ATMALDH1A1LMNA | |
| SCHEMBL7306693 | 0.81 | KMT2A (0.36) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL7302241 | 0.81 | KMT2A (0.36) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL26078627 | 0.81 | KMT2A (0.36) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL14288714 | 0.81 | MMP2 (0.42) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL7308325 | 0.81 | KMT2A (0.36) | KMT2AMEN1ATMMAPTALDH1A1 | |
| SCHEMBL16367126 | 0.81 | KMT2A (0.36) | KMT2AMEN1ATMMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | claimed |
| CN-1942438-A | Proline derivatives as pharmaceutical active ingredients in the treatment of tumors | SALAMA Z B (DE) | 2007-04-04 | — | — | CN | claimed |
| EP-1711462-A1 | PROLINE DERIVATIVES USED AS PHARMACEUTICAL ACTIVE INGREDIENTS FOR THE TREATMENT OF TUMOURS | Salama, Zoser B. nat.rer.Dr. (DE) | 2006-10-18 | — | — | EP | claimed |
| WO-2005058816-A1 | PROLINE DERIVATIVES USED AS PHARMACEUTICAL ACTIVE INGREDIENTS FOR THE TREATMENT OF TUMOURS | SALAMA ZOSER B (DE) | 2005-06-30 | — | — | WO | claimed |
| US-20250295157-A1 | METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF WEIGHT LOSS | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-09-25 | — | — | US | disclosed |
| US-12349713-B2 | Methods for the improvement and maintenance of weight loss | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-07-08 | — | — | US | disclosed |
| EP-4099849-A1 | COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF GLUCOSE METABOLISM IN CHILDHOOD AND ADOLESCENCE | Société des Produits Nestlé S.A. (CH) | 2022-12-14 | — | — | EP | disclosed |
| US-20220369685-A1 | COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF GLUCOSE METABOLISM IN CHILDHOOD AND ADOLESCENCE | NESTLE SA (CH) | 2022-11-24 | — | — | US | disclosed |
| US-20220338521-A1 | COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF WEIGHT LOSS | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2022-10-27 | — | — | US | disclosed |
| CN-114980753-A | Compositions and methods for improving and maintaining glucose metabolism in children and adolescents | 雀巢产品有限公司 | 2022-08-30 | — | — | CN | disclosed |
| EP-4033922-A1 | COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF WEIGHT LOSS | Société des Produits Nestlé S.A. (CH) | 2022-08-03 | — | — | EP | disclosed |
| CN-114423304-A | Compositions and methods for improvement and maintenance of weight loss | 雀巢产品有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-7727530-B2 | Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody | SALAMA ZOSER B | 2010-06-01 | — | — | US | disclosed |
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | SALAMA ZOSER B | 2008-07-24 | — | — | US | disclosed |
| EP-1907398-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-09 | — | — | EP | disclosed |
| CN-1942438-A | Proline derivatives as pharmaceutical active ingredients in the treatment of tumors | SALAMA Z B (DE) | 2007-04-04 | — | — | CN | disclosed |
| WO-2007011284-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| EP-1711462-A1 | PROLINE DERIVATIVES USED AS PHARMACEUTICAL ACTIVE INGREDIENTS FOR THE TREATMENT OF TUMOURS | Salama, Zoser B. nat.rer.Dr. (DE) | 2006-10-18 | — | — | EP | disclosed |
| US-20050276810-A1 | Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody | SALAMA ZOSER B | 2005-12-15 | — | — | US | disclosed |
| WO-2005058816-A1 | PROLINE DERIVATIVES USED AS PHARMACEUTICAL ACTIVE INGREDIENTS FOR THE TREATMENT OF TUMOURS | SALAMA ZOSER B (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176923-A1 | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | PREP, PRAP1, VHL | KMT2A 2637/4885MEN1 660/4885ATM 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.